| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Tryptophan 2,3-dioxygenase {ECO:0000255|HAMAP-Rule:MF_03020}, TDO {ECO:0000255|HAMAP-Rule:MF_03020}, 1131111 {ECO:0000255|HAMAP-Rule:MF_03020}, Tryptamin 2,3-dioxygenase {ECO:0000255|HAMAP-Rule:MF_03020}, Tryptophan oxygenase {ECO:0000255|HAMAP-Rule:MF_03020}, TO {ECO:0000255|HAMAP-Rule:MF_03020}, TRPO {ECO:0000255|HAMAP-Rule:MF_03020}, Tryptophan pyrrolase {ECO:0000255|HAMAP-Rule:MF_03020}, Tryptophanase {ECO:0000255|HAMAP-Rule:MF_03020}, TDO2 {ECO:0000255|HAMAP-Rule:MF_03020}, TDO |
| Entrez GeneID | 6999 |
| WB Predicted band size | 47.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This TDO2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human TDO2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于TDO2(N-term)抗体的3篇参考文献摘要概括：
1. **文献名称**：*Tryptophan 2.3-dioxygenase (TDO2) expression in human brain tumors and its potential role in immune regulation*
**作者**：Smith A, et al.
**摘要**：研究通过免疫组化(IHC)和Western blot验证了TDO2(N-term)抗体在胶质母细胞瘤组织中的特异性，发现TDO2高表达与肿瘤微环境中色氨酸代谢抑制和免疫逃逸相关。
2. **文献名称**：*Characterization of a novel TDO2 antibody targeting the N-terminal domain for cancer biomarker studies*
**作者**：Li X, et al.
**摘要**：报道了一种新型TDO2(N-term)抗体的开发，通过重组人TDO2蛋白和小鼠模型验证其特异性，并应用于肝癌患者血清样本检测，显示其作为诊断标志物的潜力。
3. **文献名称**：*TDO2-mediated tryptophan catabolism modulates neuronal inflammation in Alzheimer's disease*
**作者**：Wang Y, et al.
**摘要**：利用TDO2(N-term)抗体进行脑组织免疫荧光分析，发现阿尔茨海默病模型中TDO2在神经元中异常激活，促进神经炎症，抗体特异性通过TDO2敲除小鼠模型确认。
注：以上文献信息为示例性内容，实际引用需根据具体研究补充真实文献来源。
The TDO2 (N-term) antibody is designed to target the N-terminal region of tryptophan 2.3-dioxygenase 2 (TDO2), a heme-containing enzyme involved in the kynurenine pathway of tryptophan metabolism. TDO2 catalyzes the rate-limiting step in converting tryptophan to N-formylkynurenine, which is further processed into metabolites like kynurenine. This enzyme is primarily expressed in the liver but is also found in the brain, placenta, and certain cancer cells. Unlike its homolog IDO1 (indoleamine 2.3-dioxygenase 1), which is induced by inflammatory signals, TDO2 is often constitutively active and plays a critical role in regulating systemic tryptophan levels and immune tolerance.
The TDO2 (N-term) antibody is widely used in research to study TDO2 expression, localization, and function, particularly in contexts like cancer immunology, neurodegenerative diseases, and metabolic disorders. Overexpression of TDO2 in tumors has been linked to immunosuppression, as tryptophan depletion in the microenvironment inhibits T-cell activity, enabling immune evasion. By detecting TDO2 via techniques such as Western blotting, immunohistochemistry, or immunofluorescence, researchers can explore its role in disease progression and therapeutic targeting.
This antibody’s specificity for the N-terminal region ensures minimal cross-reactivity with related enzymes, making it a valuable tool for distinguishing TDO2 from other dioxygenases. Its applications extend to both basic research and drug development, where modulating TDO2 activity is being investigated as a strategy to enhance anticancer immunity or treat neurological conditions associated with kynurenine pathway dysregulation.
×
